Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Remedy Entertainment Plc – Correction: Adoption of IFRS and unaudited IFRS comparison figures

Remedy Entertainment Plc | Company Announcement 10.15 a.m. (EEST) 26 April 2022 Remedy Entertainment Plc – Correction: Adoption of IFRS and unaudited IFRS comparison figures Remedy Entertainment yesterday 25.4.2022 published a release titled Adoption of IFRS and unaudited IFRS comparison figures. During the release publishing process, there was a technical problem which caused the English version of the release to lack the Capitalization of Development Costs title row in the tables “Statement of comprehensive income 1 October – 31 December 2021 and 1 January – 31 December 2021” and “

Reminder: Invitation to DNB's first quarter presentation, Thursday, 28 April 2022

DNB will publish its results for the first quarter of 2022 on Thursday, 28 April 2022 at 7.30 CET. 9:30 CET: Presentation CEO Kjerstin Braathen and CFO Ida Lerner present the results at a live streamed press conference. A broadcast will be available on the Investor Relations pages at ir.dnb.no. It will also be possible to physically attend to the presentation at DNB's head office in Bjørvika, Dronning Eufemias gate 30. Please register your attendance in Oslo, at ca@dnb.no. 13:30 CET: Conference call for analysts and investors Call in details: Norway +47 21 56 33 18, UK Wide +44 (

Valio to sell its Russian operations

Valio has completed negotiations on the divestment of its Russian operations. Valio will sell the operations to Velkom Group. The transaction will take place immediately.With the transaction, Valio’s personnel in Russia will transfer to Velkom Group. The parties have decided not to disclose the value of the transaction. With the completed transaction, Valio’s operations in Russia have now ended. The transaction includes Valio’s Russian operations and the processed cheese factory in Ershovo. The Viola® brand processed cheese sold and produced in Russia is also part of the transaction,

ANNOUNCEMENT OF THE NAV OF P CAPITAL PARTNERS IV

Stockholm, 26 April 2022 Today the Net Asset Values of the P Capital Partners IV participation loan debentures is at the close of business on 25 April 2022 EUR 97.40 per each of the series A1 participation loan debentures. The Net Asset Value of P Capital Partners IV participation loan debentures is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The Net Asset Value has been set, as a result of P Capital Partners IV increasing its contributed capital by EUR 15.5 million, through the issuance of 161,952 series A1 participation

ANNOUNCEMENT OF THE NAV OF P CAPITAL PARTNERS IV B

Today the Net Asset Values of the P Capital Partners IV B participation loan debentures are being announced. At the close of business on 25 April 2022, the Net Asset Value of the series A1 participation loan debentures amounted to EUR 97.20 each, and the Net Asset Value of the series B participation loan debenture amounted to EUR 972.18 each. The Net Asset Value of P Capital Partners IV B participation loan debentures is to be calculated at the close of each quarter and in conjunction with a capital increase or decrease. The Net Asset Value has been set as a result of P Capital

A faster pace and higher targets in LKAB's transition towards a sustainable future

LKAB is now boosting both the pace and the level of ambition in its plans towards the transition to carbon-dioxide-free sponge iron. A successful exploration programme with dramatically increasing mineral resources means that the plan for future production of sponge iron has been upped to 24.4 million tonnes by 2050. This will enable a reduction in carbon dioxide emissions among global steel industry customers corresponding to nearly all of Sweden's current greenhouse gas emissions."The climate can't wait and demand for the raw material for producing fossil-free steel is already upon us –

BioStock: Ultimovacs protects cancer vaccine technology until 2037

Norwegian biotech Ultimovacs has announced receiving a Notice of Allowance from the U.S. Patent and Trademark Office regarding its universal cancer vaccine UV1 in combination with various classes of checkpoint inhibitors. Once formally granted, the patent will protect Ultimovacs’ technology until at least June 2037.Read the article at biostock.se : https://www.biostock.se/en/2022/04/ultimovacs-protects-cancer-vaccine-technology-until-at-least-2037/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Trelleborg acquires US healthcare & medical company

Trelleborg Group has, through its business area Trelleborg Sealing Solutions, signed an agreement and finalized the acquisition of the US-based company EirMed, LLC. The company specializes in technical precision plastic injection-molded components, which are mainly applied in medical devices, such as those used for in-vitro diagnostics, minimally invasive surgery, and orthopedics.   The company has its head office and manufacturing in Menomonie, Wisconsin, in the US. Sales amounted to approximately SEK 100 M in 2021.   The healthcare & medical market is expected to report stable

UPM Interim Report Q1 2022: Strong performance supported by tight markets

UPM-Kymmene Corporation        Stock Exchange Release (Interim Report)        26 April 2022 at 09:50 EEST UPM Interim Report Q1 2022:Strong performance supported by tight markets Q1 highlights · Sales increased by 12% to EUR 2,507 million (2,234 million in Q1 2021) · Comparable EBIT was in line with last year at EUR 277 million, 11.0% of sales (279 million, 12.5%) · Operating cash flow was EUR 12 million (217 million) · Net debt increased to EUR 837 million (83 million) and net debt to EBITDA ratio was 0.46 (0.06) · Sales prices increased in all business areas and

QUARTERLY REPORT, FIRST QUARTER 2022

  Press release: Stockholm, April 26, 2022, 08.45 CET HIGHLIGHTS OF THE FIRST QUARTER 2022 · Net sales was 114 MSEK compared to the previous year 95 MSEK. Major positive contributors were favourable development of zinc price and produced amount of gold and zinc  · EBITDA was 38 MSEK (14) · EBIT was 15 MSEK (-6) · Cash and cash equivalents were 44 MSEK (26) · Investments were 13 MSEK (8) · The production was about 336 000 (344 000) ounces of silver, 870 (707) ounces of gold, 465 (309) tonnes of lead, and 990 (664) tonnes of zinc in concentrates · The

Carbiotix completes expansion of research and development laboratory

Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has completed the expansion of its research and development laboratory in Lund, Sweden. The expansion of a third laboratory will provide us separate laboratories for LinkGut sample analysis, microbial therapeutic research, and prebiotic ingredient development. The laboratory expansion will also provide additional office space that will allow the Company to bring together all personnel based in Lund into one office and laboratory area. The expansion allows Carbiotix to ramp up research and development activities

Mandatory notification of trade

Anooj Unarket, Board member of Otello Corporation ASA, has on behalf of certain related parties, as of 25th April 2022, acquired interests in shares of Otello Corporation ASA. The balance of Anooj Unarket and related parties’ holdings after the transaction totals 27,755,037 shares. Please refer to the attached notification of trading for further details. This information is subject to disclosure requirements in regulation EU 596/2014 article 19 number 3 and the Norwegian Securities Trading Act section 5-12.

Realheart to recruit new CFO

Press release 26 April, 2022 Realheart has initiated the process of recruiting a new Chief Financial Officer to take over when current CFO Andreas Hultdin leaves on 31 July.Realheart is a Swedish company headquartered in Västerås, which is developing the world's first artificial four-chamber heart. The company has recently taken several important steps forward, not least in leaving the prototype behind and instead test the clinical version of the Realheart TAH in the animal studies that are about to be initiated. ''As we step by step move closer the clinical trial phase, we see

Interim report January–March 2022 – Pricer AB (publ)

High order intake of 24.4% and net sales growth of 18.6 %   Q1 2022   · Net sales amounted to SEK 465.9 M (392.9) an increase of 18.6 percent compared to the same period last year. · Operating profit amounted to SEK -9.7 M (17.3), which corresponds to an operating margin of -2.1 percent (4.4). · Order intake was 551 MSEK (443), an increase of 24,4 percent compared to the same period last year. · Order backlog amounted to SEK 464 M (550), of which the majority is expected to be delivered in Q2 and Q3 2022. · Profit for the period was SEK -9.5 M (17.7). · Earnings

Genova has entered into new financing agreements of approximately SEK 3,200m

Genova Property Group AB (publ) has entered into new financing agreements with Swedbank AB (publ) for a total of SEK 3,200m, of which SEK 350m consists of a revolving credit facility. The new facilities relate to Genova's existing investment property portfolio and comprise a total of 43 properties. The refinancing also strengthens Genova's liquidity by almost SEK 170m. The new financing agreements will mature in May 2027, with an average maturity of approximately 4 years. The new financing agreements are based on Genova's green framework and can be converted to green financing when

Invitation – presentation of Cary Group’s report of the first quarter 2022

Cary Group will publish its first quarter results on Tuesday, May 10, 2022 at approximately 08:00 AM CET. A conference call for investors, analysts and financial media will be held at 10:00 AM CET.The report will be presented by Anders Jensen, CEO, as well as by Joakim Rasiwala, CFO. The telephone conference will be webcasted live at www.carygroup.com where presentation material will be available as soon as the report is released. Dial-in details for the conference call: SE: +46 8 566 42 705UK: +44 333 300 92 67US: +1 6 319 131 422 PIN US: 91572095# For more information,

Gasum obtains LNG distribution license in Belgium

The Nordic energy company Gasum has obtained a distribution license for liquified natural gas (LNG) on the Belgian market. The distribution license allows Gasum to expand its supply network and guarantees safe and high-quality deliveries of LNG to customers bunkering in Belgium.Gasum expands the outreach and quality of its maritime LNG offering and further improve the service to its shipping customers. As part of this strategy, Gasum has now obtained a license to deliver LNG for maritime customers in Belgium. The new LNG distribution license obtained on March 17, 2022, will allow Gasum

TePe publishes its 2021 Sustainability Report

Oral care company TePe Oral Hygiene Products AB has now published its annual Sustainability Report, highlighting progress and improvements of 2021. The report is available at www.tepe.com.“At TePe, we want to contribute to positive change and continue creating value for our customers and consumers. Besides promoting health and wellbeing, our teams have put tremendous efforts into reducing the carbon footprint of our products and packaging by means of continuous improvements, shifting to renewable sources, and using green energy”, says Hanna Hageberg Hammar, CEO of TePe.  Selected

Pilloxa provides digital patient support solution for Type 1 Diabetes/Addison’s Disease trial at Sahlgrenska University Hospital

Stockholm, Sweden, April 26, 2022: Digital health company Pilloxa today announced they have signed a collaboration to provide a digital patient support solution based on their software and smart pillbox for a trial to be conducted at Sahlgrenska University Hospital involving patients with Type 1 Diabetes and Addison’s Disease. The project involves the Department of Endocrinology-Diabetes-Metabolism at Sahlgrenska University Hospital as well as the Department of Internal Medicine and Clinical Nutrition at the Institute of Medicine at Sahlgrenska Academy within the University of Gothenburg.

Elicera Therapeutics AB (publ) Interim Report 1 January – 31 March 2022

First quarter (January-March 2022) · Operating profit/loss totaled SEK -4,741,051 (-2,404,551). · Loss for the period totaled SEK -4,754,615 (-2,404,489). · Cash flow from operating activities totaled SEK -5,333,226 (-3,481,034). · Earnings per share before dilution totaled SEK -0.24 (-0.20) Earnings per share after dilution amounted to SEK -0.24 (-0.20).   Key events during the first quarter · Elicera Therapeutics boosted IP protection for ELC-100 through the acquisition of patents from Immunicum. · Elicera Therapeutics secured SEK 5 million in grant financing

Metso Outotec introduces a comprehensive Tailings Management Solutions portfolio

Metso Outotec Corporation’s press release on April 26, 2022, at 09:00 a.m. EESTMetso Outotec is introducing its comprehensive Tailings Management Solutions offering for the sustainable management of mine tailings. The offering unites the company’s frontrunning products with decades of process expertise and covers tailings thickening and dewatering as well as handling through conveying and dry stacking. In addition, Metso Outotec offers a frontrunning portfolio of solutions for the treatment of water produced during dewatering, enabling closed water loops while managing the level of

AcuCort applies for ethical review for a questionnaire study on allergy treatment

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces today that the company has submitted an ethical review application to the Swedish Ethical Review Authority regarding a questionnaire study. The purpose of the study is to document how allergy patients value their treatment. The questionnaire study is an important part of the future pricing and reimbursement application to the Swedish Dental and Pharmaceutical Benefits Agency, TLV.ISICORT® is a thin, small fast-dissolving oral film that is placed on the tongue where the active anti-inflammatory substance, dexamethasone, dissolves

Getinge Interim Report January-March 2022: Healthy order book but supply chain challenges

“Net sales declined by 6.4% and the order intake fell organically by 4.4% in the quarter,” says Mattias Perjos, President & CEO. ”However, excluding the strong sales of ventilators in 2021, we had organic growth in both order intake and net sales. The order book grew 8% during the quarter and is 21% higher now than the same period in 2021, excluding currency fluctuations”.Getinge has a strong pipeline of orders and the sales forecast for the full-year remains unchanged. The deliveries were negatively affected toward the end of the quarter as a result of temporary supply chain challenges.

There are no items matching the current filter
There are no more items matching the current filter
Back to top